3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
9
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Rectal Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
52
Radiotherapy
24
Bevacizumab
23
Radiation
10
Magnetic Resonance Spectroscopy
7
Lomustine
7
Carmustine
7
Radiosurgery
6
Surgical Procedures, Operative
5
Irinotecan
5
Aminolevulinic Acid
5
Radiotherapy, Intensity-Modulated
4
Nivolumab
4
Ipilimumab
4
Erlotinib Hydrochloride
4
Cilengitide
4
vocimagene amiretrorepvec
3
vitespin
3
sargramostim
3
poly ICLC
3
pembrolizumab
3
fluoromisonidazole
3
carmustine, poliferprosan 20 drug combination
3
Vorinostat
3
TPI-287
3
O(6)-benzylguanine
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Flucytosine
3
Dynamic Contrast Enhanced Magnetic Resonance Imaging
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Glioblastoma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts